Press releases
Correction of press release: Liproca Phase IIb study results indicate cancer control Liproca Phase IIb study results indicate cancer control LIDDS announces positive meeting with the Swedish Medical Products Agency, confirming the Liproca® Depot Phase III study design
Kommuniké från årsstämman i LIDDSCompany Analysis
Photo Library
Lidds
LIDDS develops effective pharmaceutical products for cancer and other diseases with the patented NanoZolid® technology. NanoZolid releases the medication locally and effectively which means significantly fewer side effects compared with systemic treatment allowing a controlled, sustained and customized release of medication for up to six months.
Visitingadress: Virdings allé 32b, Uppsala
SE-754 50, Sweden. +46 00 44 55 66 info@liddspharma.com
Subscribe for news
Press releases
- 2020-05-19 Correction of press release: Liproca Phase IIb study results indicate cancer control
- 2020-05-19 Liproca Phase IIb study results indicate cancer control
- 2020-05-18 LIDDS announces positive meeting with the Swedish Medical Products Agency, confirming the Liproca® Depot Phase III study design
- 2020-05-14 Kommuniké från årsstämman i LIDDS
LIDDS AB (publ) Org No.: 556580-2856, Virdings allé 32B, 754 50 UPPSALA, www.liddspharma.com
